PharmaLytica 2021 Hyderabad review.

Dr Reddy's partners with Department of Biotechnology for Sputnik V vaccine clinical trials in India

November 2, 2020

Dr Reddy' s Laboratories Ltd on Thursday announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), for advisory support on clinical trials of Sputnik V vaccine in India.

According to a press release from the city-based drug maker, the partnership will allow Dr Reddy' s to identify and use some of BIRAC's clinical trial centres for the vaccine, which are funded under the National Biopharma Mission (NBM), implemented by Project Management Unit-NBM at BIRAC.

Further, the company will have access to Good Clinical Laboratory Practice (GCLP) labs to conduct immunogenicity assay testing of the vaccine. Immunogenecity refers to the ability of an antigen to induce an immune response.

Chairman of Dr Reddys Laboratories, Satish Reddy said, "We are pleased with the collaboration with BIRAC as an advisory partner for clinical trials of the Sputnik V vaccine in India. We look forward to working with them to accelerate our efforts in bringing the vaccine to India."


This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More